U2opia Technology, a consortium of technology and administrative executives with extensive experience in both industry and defense, has exclusively licensed two technologies from ORNL that offer a new method for advanced cybersecurity monitoring in real time.
A partnership of ORNL, the Tennessee Department of Economic and Community Development, the Community Reuse Organization of East Tennessee and TVA that aims to attract nuclear energy-related firms to Oak Ridge has been recognized with a state and local economic development award from the Federal Laboratory Consortium.
Having lived on three continents spanning the world’s four hemispheres, Philipe Ambrozio Dias understands the difficulties of moving to a new place.
Over the past seven years, researchers in ORNL’s Geospatial Science and Human Security Division have mapped and characterized all structures within the United States and its territories to aid FEMA in its response to disasters. This dataset provides a consistent, nationwide accounting of the buildings where people reside and work.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
It’s a simple premise: To truly improve the health, safety, and security of human beings, you must first understand where those individuals are.
A team of researchers has developed a novel, machine learning–based technique to explore and identify relationships among medical concepts using electronic health record data across multiple healthcare providers.
Tackling the climate crisis and achieving an equitable clean energy future are among the biggest challenges of our time.
ORNL scientists had a problem mapping the genomes of bacteria to better understand the origins of their physical traits and improve their function for bioenergy production.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.